Clinical infrastructure for psychedelic medicine.
Trellis captures, structures, and standardizes the clinical data that psychedelic trials and clinics generate — from session through long-term outcomes.
Get in touch
PCDM Standard
A shared schema for substances, session phases, instruments, and outcomes.
Purpose-built for the modality
Psychedelic-assisted therapy doesn't fit inside the systems the rest of clinical medicine runs on. Six-hour dosing sessions, two-clinician dyad teams, Schedule I chain-of-custody, and longitudinal integration follow-up weren't part of the original design brief for generic trial management software or single-clinic EMRs.
Trellis is purpose-built for those workflows. We give clinics and trial sponsors a unified data layer — one that captures what actually happens in a session, structures it against an open data model, and makes it ready for regulatory submission, outcomes reporting, and real-world evidence.
Capture at the source
Validated instruments, session documentation, vitals, and safety events — collected where the care happens, not reconstructed after the fact.
One data model
The Psychedelic Common Data Model (PCDM) gives the field a shared schema for substances, session phases, validated instruments, and outcomes. Open spec, OMOP-compatible, MedDRA-mapped.
Built for regulatory weight
21 CFR Part 11-grade architecture, HIPAA-compliant, designed to be submission-ready from the first session — not retrofitted later.
Evidence that compounds
Every clinic and trial that captures into Trellis strengthens the benchmarks, outcomes, and real-world evidence available to the field.
Who Trellis is for
Clinics
Psychedelic clinics and treatment programs running ketamine-assisted therapy today and preparing for the next wave of approvals.
Trial Sponsors & CROs
Running psychedelic clinical programs that need workflow, capture, and reporting purpose-built for the modality.
Researchers
Academic centers and investigators building the evidence base for the field with standardized capture.
Expanded Access
Sites capturing rigorous real-world data under the federal expanded access pathway.
The transition to mainstream clinical practice
The clinical, regulatory, and policy environment for psychedelic medicine has moved faster than the infrastructure supporting it. New federal guidance, expanded access pathways, and a growing pipeline of late-stage trials are bringing psychedelic treatment closer to mainstream clinical practice. The data infrastructure to support that transition hasn't existed at the scale the field now requires. Trellis is building it.
Building, investing, or operating in psychedelic medicine?
We'd like to hear from clinical advisors, design partners, sponsors, and investors.
Contact Trellis →